Ratg denied due to quantity / dose limits by Humana?

Humana Medicare Advantage plans must follow CMS coverage guidelines, and services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS), under which all medical care, services, supplies and equipment must be medically necessary . Under CMS NCD 260.7, the FDA has approved lymphocyte immune globulin, anti-thymocyte globulin (equine) for the management of allograft rejection episodes in renal transplantation, it is covered under Medicare when used for this purpose, and other forms of lymphocyte globulin preparation that the FDA approves for this indication may be covered . The FDA-labeled indication for rabbit ATG is that Thymoglobulin (anti-thymocyte globulin, rabbit) is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , with the approved regimen being 1.5 mg/kg of body weight administered daily for 4 to 7 days . Per FDA labeling, Thymoglobulin is contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression , and dose reductions are required when the WBC count is between 2,000 and 3,000 cells/mm3 or if the platelet count is between 50,000 and 75,000 cells/mm3 . Humana requires prior authorization through its transplant network: preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300 or by phone at 866-421-5663 , and Humana MA may apply step therapy requirements for some drugs under its Part B Step Therapy Preferred Drug List. To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment, though Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment .

- For kidney transplant rejection prophylaxis or treatment, the request aligns squarely with the FDA label: Thymoglobulin is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , and the drug is indicated for management of allograft rejection episodes in renal transplantation and is covered under Medicare when used for this purpose per CMS NCD 260.7 - KDIGO clinical practice guidelines support ATG-based induction in kidney transplant recipients, particularly those at high immunologic risk; anti-thymocyte globulin is a highly efficient induction agent that can prevent acute rejection and delayed graft function and is widely used for biopsy-confirmed acute rejection reversal and steroid-resistant rejection - For steroid-resistant or vascular rejection, ATG is the guideline-endorsed standard: ATG is a pivotal immunosuppressive therapy utilized in the management of T-cell-mediated rejection and steroid-resistant rejection among renal transplant recipients ; an IL-2 receptor antagonist (basiliximab) is not an appropriate substitute for treatment of established rejection, so step-therapy requirements should be waived - Dosing requested matches the FDA-approved regimen of 1.5 mg/kg of body weight administered daily for 4 to 7 days for induction, or a 7 to 14 day course of daily infusion of 1.5 mg/kg of Thymoglobulin for treatment of acute rejection, consistent with the package insert and LiverTox/NIH summaries - Thymoglobulin is preferred over equine ATG in high-risk recipients: multiple studies have indicated that thymoglobulin is favored in comparison to other induction agents for patients who have increased risk of developing post-transplant complications, such as elderly patients, patients undergoing a repeat transplantation, and patients in which minimization of use of steroids or CNIs post-operation is recommended — relevant for the Medicare Advantage population - Humana's own policy framework grants continuity-of-care protection: Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment , and members can request expedited exception reviews for step therapy prior authorization requests - Contraindication-based denials should be rebutted with documentation that the patient has no history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or active acute or chronic infections that contraindicate any additional immunosuppression , satisfying the only FDA-labeled contraindications

## Why Humana Limits rATG Quantities — and Why You Can Appeal

Rabbit anti-thymocyte globulin (rATG) is a specialized immunosuppressive agent used in organ transplantation and serious hematologic conditions such as aplastic anemia. Humana applies quantity limits to this medication based on its coverage and utilization-management policies, which set boundaries on the number of vials, doses, or treatment days covered per authorization period. These limits are designed for "typical" patients and frequently do not account for individual clinical circumstances — transplant rejection episodes, body weight, renal function, or disease severity — that legitimately require a higher or extended course.

## Why This Denial Is Appealable

Quantity-limit denials are among the most commonly overturned on appeal when a prescriber documents a clear medical rationale. The FDA-approved prescribing information for rATG specifies dosing guidance that your transplant or hematology team must follow; if the quantity required to complete the prescribed regimen exceeds Humana's limit, the gap between the policy limit and the label-directed regimen is the core of your appeal. You are entitled to request the exact language of Humana's quantity-limit policy for this drug and map your prescriber's order directly against it.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe listed on your denial notice (typically 180 days for ERISA plans; confirm your plan documents).
• External review: Under ACA Section 2719, if your plan is subject to the ACA, you may request independent external review after exhausting internal remedies. The standard external-review window is approximately 4 months from the final internal denial. An expedited external review is available when a standard timeline would seriously jeopardize your health — applicable here given the acute or post-transplant context in which rATG is used.
• ERISA plans (most employer-sponsored plans) must provide a full-and-fair review under ERISA Section 503, including access to the clinical criteria used.

## Appeal Timeline

1. Request the denial reason in writing and the specific policy language used. 2. File the internal appeal; submit prescriber letter and supporting records within the plan's deadline. 3. If denied internally, file for external review immediately. 4. Keep copies of all submissions and confirmation numbers.

## Documentation to Gather

• Diagnosis confirmation: Records establishing the condition requiring rATG (e.g., transplant status, aplastic anemia diagnosis, rejection episode).
• Prescriber medical-necessity letter: Your specialist should explain why the quantity ordered — consistent with the FDA-approved prescribing label — is required for your specific body weight, clinical course, and treatment protocol.
• Treatment history: Prior immunosuppressive therapy with dates and outcomes where relevant.
• Clinical severity documentation: Recent labs, biopsy results, or clinical notes demonstrating disease status.

## Criteria-Mapping Structure

Obtain Humana's published medical or pharmacy coverage policy for rATG. List each requirement side by side with the corresponding documentation from your medical record:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Approved indication (e.g., transplant rejection / aplastic anemia) | Diagnosis codes + specialist notes | | Prescriber specialty requirement | Prescribing physician credentials | | Quantity/days within policy limit OR exception basis | Prescriber letter citing FDA label dosing and patient-specific factors |

The goal is to show that every element Humana requires is present in your record, and that the quantity ordered is the minimum necessary per the approved prescribing label.